QCDx, a Farmington, Conn.-based diagnostics firm specializing within the detection and characterization of circulating tumor cells (CTCs), closed a $7m financing.
The financing comprised $5.3m in intermediate time period debt underneath a credit score facility and the conversion of $1.7m in present convertible notes into fairness. This marks the preliminary closing underneath a deliberate $15m intermediate time period credit score facility. Sagittarius Advisors LLC was the executive agent underneath the power.
The proceeds from this financing will allow the achievement of a number of key milestones together with launch of:
- a brand new diagnostic instrument;
- a breast most cancers monitoring assay;
- proprietary multiplex immunofluorescence reagent kits; and
- a CLIA -certified scientific laboratory.
Led by Triantafyllos Tafas, PhD, Founder and CEO, QCDx is a diagnostics firm specializing within the detection and characterization of circulating tumor cells (CTCs).
They develop proprietary liquid biopsy applied sciences for the enrichment-free detection and proteomic profiling of circulating tumor cells (CTCs), empowering oncologists with real-time insights into tumor heterogeneity, therapeutic targets, and illness development. The corporate delivers its capabilities via each superior medical instrumentation and CLIA-certified laboratory companies.
QCDx plans to finish a breast most cancers scientific validation research in partnership with UCONN Well being and relocate to its new CLIA-certified laboratory facility this yr.
FinSMEs
01/05/2025
